Nearly 1 million Americans live with multiple sclerosis (MS), an immune-mediated disorder of the central nervous system that typically begins between ages 20 and 50. MS was once considered an inevitably progressive and disabling disease; today, with more than 20 disease-modifying therapies and improved early diagnosis, many people maintain near-normal function for decades. The condition affects women roughly two to three times more often than men, and rates are higher at higher latitudes — a clue to its complex origins.
This guide covers MS types, symptoms, diagnosis, and the current treatment landscape in plain language. It is educational and is not a substitute for evaluation and ongoing care by a neurologist. For more on related autoimmune and neurological conditions, see our medical conditions resource hub.
What MS Is
MS is an immune-mediated condition in which the body’s own immune cells (T cells and B cells) attack myelin — the insulating sheath surrounding nerve fibers in the brain, spinal cord, and optic nerves. This inflammation produces lesions that are visible on MRI. Over time, damage can extend to the underlying nerve fibers (axons), which contributes to the more fixed disability seen in advanced disease. Because the damage disrupts the electrical signals between the brain and the rest of the body, symptoms depend heavily on where the lesions are.
According to the National Institute of Neurological Disorders and Stroke (NINDS) and the National Multiple Sclerosis Society (NMSS), MS is one of the most common causes of non-traumatic neurological disability in young adults. Onset typically occurs between ages 20 and 50, though MS can also occur in children (pediatric MS) and, less commonly, in older adults.
The Types of MS
Relapsing-remitting MS (RRMS) is the most common form at diagnosis (roughly 85% of cases). It involves discrete relapses with new neurologic symptoms followed by complete or partial recovery. In classic RRMS, the periods between relapses show no ongoing progression of disability.
Secondary progressive MS (SPMS) develops in many people with RRMS eventually, with a more gradual worsening between (or in the absence of) relapses. Before modern treatments, the natural history showed roughly half of RRMS transitioning to SPMS within 10 to 15 years; current therapies appear to have substantially modified this trajectory, though long-term data are still evolving.
Primary progressive MS (PPMS) affects about 10 to 15% of people with MS and involves gradual worsening from onset without distinct early relapses. Clinically isolated syndrome (CIS) describes a first MS-like episode; some people with CIS go on to develop clinically definite MS, while others have a single event. Clinicians increasingly describe MS in terms of whether it is active (new relapses or new MRI lesions) and whether it is progressing, because that framing guides treatment decisions.
Common Symptoms
Symptoms depend on lesion location and vary widely from person to person. Common presentations include optic neuritis (vision loss or blurring with painful eye movement), sensory symptoms (numbness, tingling, or an electric-shock sensation running down the spine with neck flexion, known as Lhermitte’s sign), motor weakness, balance and coordination problems, dizziness, and bladder or bowel dysfunction.
Per Mayo Clinic, fatigue is the most common and often most disabling symptom, affecting roughly 80% of people with MS. Cognitive changes — particularly slowed processing speed and memory difficulty — affect roughly half of people at some point. Spasticity, neuropathic pain, sexual dysfunction, and depression are also common. Because these symptoms overlap with many other conditions, a symptom alone does not diagnose MS.
Triggers of Relapse and Worsening
Heat sensitivity (Uhthoff’s phenomenon) produces a temporary worsening of symptoms when body temperature rises — from hot weather, a hot shower, fever, or exercise. This is not a true relapse; it reflects impaired conduction in already-damaged nerves and resolves when the person cools down. Genuine relapses, by contrast, involve new or clearly worsening symptoms that last more than 24 hours. Infections and, in some people, significant stress can trigger true relapses.
Pregnancy tends to reduce relapse risk during the second and third trimesters but is associated with increased relapse risk in the postpartum period. Vitamin D deficiency, low sun exposure, smoking, and obesity are all associated with a worse MS course in observational studies, which is why clinicians often address these modifiable factors.
Causes and Risk Factors
MS results from an interaction between genetic susceptibility and environmental triggers; it is not caused by any one thing, and it is not contagious. Genetics contribute moderately: having a first-degree relative with MS raises lifetime risk to roughly 2 to 4% (versus about 0.3% in the general population). The HLA-DRB1*15:01 variant is the strongest single common genetic risk factor.
Environmental and lifestyle factors include prior Epstein-Barr virus (EBV) infection — a large 2022 study of U.S. military personnel found that EBV infection preceded nearly all cases of MS and was associated with a large increase in risk — along with vitamin D deficiency, low sun exposure, smoking, adolescent obesity, and certain other exposures. The geographic gradient, with higher prevalence farther from the equator, has been recognized for decades. Having a risk factor does not mean a person will develop MS; these are associations, not certainties.
Diagnosis
MS is diagnosed using the McDonald criteria, which require evidence of central nervous system damage separated in time and in space (in other words, in different locations and at different points in time). There is no single blood test that confirms MS. MRI of the brain and spinal cord is the cornerstone, showing characteristic white-matter lesions in periventricular, juxtacortical/cortical, infratentorial, and spinal cord locations; active lesions may enhance with gadolinium contrast.
Spinal fluid analysis can support the diagnosis (oligoclonal bands are present in the great majority of people with MS). Visual evoked potentials may reveal subclinical optic nerve involvement. The differential diagnosis is broad and includes neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disease, vasculitis, vitamin B12 deficiency, Lyme disease, and other inflammatory or infectious conditions — which is one reason diagnosis belongs with a neurologist rather than with self-assessment.
Disease-Modifying Therapies
The treatment landscape has transformed since the first DMT (interferon beta-1b) was approved in 1993. More than 20 DMTs are now available, generally grouped by efficacy and mechanism. Per Cleveland Clinic and current specialty practice, many clinicians now favor starting effective therapy early to prevent the accumulation of disability. DMTs reduce relapses and new MRI activity and can slow progression, but they do not reverse existing damage and are not a cure.
Injectable agents include the interferon betas and glatiramer acetate — modest efficacy with a long, well-established safety record. Oral DMTs include dimethyl fumarate, diroximel fumarate, fingolimod, siponimod, ozanimod, ponesimod, teriflunomide, and cladribine — a range of efficacy and side-effect profiles. Infusion and higher-efficacy therapies include natalizumab, ocrelizumab, ofatumumab, ublituximab, and alemtuzumab — generally the highest efficacy, with greater monitoring requirements.
Ocrelizumab (Ocrevus) was the first DMT FDA-approved for primary progressive MS and can modestly slow progression in selected patients. Costs are substantial: many DMTs carry list prices in the range of roughly $80,000 to $100,000 or more per year, though insurance coverage, specialty pharmacy programs, and manufacturer copay assistance typically reduce out-of-pocket costs significantly. Choosing among DMTs — and deciding when to switch — is an individualized, prescriber-directed decision that weighs disease activity, risks, monitoring, pregnancy plans, and personal preference. Do not start, switch, or stop a DMT on your own; stopping some therapies abruptly can trigger a rebound of disease activity, so any change should be made with your neurologist.
Acute Relapse Treatment
Significant relapses are typically treated with a short course of high-dose corticosteroids, most often intravenous methylprednisolone over several days, sometimes followed by an oral taper. Steroids can speed recovery from an acute relapse but do not change the long-term course, and they are not used as a daily maintenance treatment. For severe relapses that do not respond to steroids, plasma exchange (plasmapheresis) is sometimes used. Steroid dosing and any taper are decided and supervised by the treating clinician for the individual situation.
Symptom Management
Beyond DMTs, treating individual symptoms substantially affects quality of life. Fatigue may be helped by addressing sleep, mood, and activity, and sometimes with medication chosen by a clinician. Spasticity is treated with agents such as baclofen or tizanidine, and sometimes onabotulinumtoxinA injections. Bladder symptoms may respond to specific medications or other measures. Neuropathic pain often responds to agents such as gabapentin, pregabalin, or duloxetine. Depression is common in MS and is treated as it is in people without MS — and it deserves attention, not stigma. All of these medications are individualized and prescriber-directed.
Physical therapy, occupational therapy, and regular exercise play essential roles. Dalfampridine (Ampyra) improves walking speed in some patients. Cooling strategies — cooling vests, scarves, and swimming — help heat-sensitive patients stay functional in warm conditions.
When to See a Doctor
Sudden vision changes, new numbness or weakness, balance problems, or other neurologic symptoms — particularly those lasting more than 24 hours — warrant prompt evaluation. Seek urgent care for a sudden severe change such as significant vision loss, new inability to walk, or loss of bladder or bowel control. Early diagnosis matters because early, appropriate DMT initiation is associated with better long-term outcomes. Most diagnosis and ongoing management occurs through neurology, often in subspecialized MS clinics.
MS care can be expensive but is largely covered by insurance. Specialty pharmacy programs, manufacturer copay assistance, and the National MS Society’s MS Navigator service can help with access and cost. Telehealth has expanded access to some MS care, though procedures such as infusions and MRI remain in-person.
Frequently Asked Questions
Is multiple sclerosis fatal?
MS is rarely directly fatal, and average life expectancy is reduced only modestly compared with the general population. Complications of advanced disease (immobility, swallowing difficulties, infections) can shorten life. Most MS-related deaths involve complications rather than the disease process itself, and modern care continues to improve outcomes.
Can MS be cured?
There is no cure for MS. However, disease-modifying therapies can substantially alter the disease course, and some people on effective DMTs reach “no evidence of disease activity” (NEDA) — no relapses, no new MRI activity, and no progression — for extended periods. In selected severe cases, autologous stem cell transplantation can produce durable remission, but it carries real risks and is done only at specialized centers. Be cautious of any product or clinic promising a cure.
Is MS hereditary?
Genetics contribute modestly. Having a first-degree relative with MS raises lifetime risk from about 0.3% to roughly 2 to 4%. Identical twins of people with MS have roughly a 25% concordance rate. MS is not a single-gene inherited disorder, and most people with MS have no affected relatives.
Should people with MS exercise?
Yes. Regular exercise is now recommended as part of MS care. It can improve fatigue, mood, mobility, and overall function, with no evidence that it triggers relapses. Heat-sensitive people may benefit from cooling strategies and aquatic exercise. Ask your care team to help tailor a program to your abilities.
Can I stop my DMT if I feel fine?
Not on your own. Feeling well often means the therapy is working. Stopping some DMTs abruptly can cause a rebound of disease activity. Any decision to pause, switch, or stop a DMT should be made together with your neurologist, who can weigh your MRI activity, age, and other factors.
The Bottom Line
Multiple sclerosis has been transformed by modern disease-modifying therapies, and many people now maintain stable function for decades. Early diagnosis and treatment matter, and current evidence generally supports earlier, often higher-efficacy DMT use — always individualized with a neurologist. Symptom management, exercise, and rehabilitation also substantially improve quality of life. If you have neurologic symptoms that could suggest MS, a prompt evaluation with neurology can shape the long-term course considerably.
Quick summary: MS is an immune-mediated disease in which the immune system damages myelin in the brain and spinal cord. It is diagnosed with the McDonald criteria and MRI, and it is treated with disease-modifying therapies that reduce relapses and slow progression but do not cure it. DMTs and relapse treatments are individualized and prescriber-directed — do not start, switch, or stop them on your own. See a neurologist for evaluation and ongoing care, and seek urgent care for a sudden severe change such as significant vision loss or new inability to walk. This article is educational and is not medical advice.
Sources
- National Multiple Sclerosis Society (NMSS) — Understanding MS, treatments, and support: nationalmssociety.org
- NINDS — Multiple Sclerosis: ninds.nih.gov
- MedlinePlus — Multiple Sclerosis: medlineplus.gov/multiplesclerosis.html
- Mayo Clinic — Multiple Sclerosis: mayoclinic.org